How to Prepare for a Regulatory Affairs Interview in 2026

Regulatory affairs interviews separate candidates who've read the regulations from those who've applied them. Hiring managers at Pfizer, J&J, Medtronic, and mid-size biotechs are not impressed by candidates who recite 21 CFR — they want to see how you think through submission strategy, handle label disputes, and navigate agency feedback.

Here's exactly what they test and how to prepare.

The Core Knowledge Areas Tested

Every RA interview — whether for a specialist, associate director, or VP role — maps to the same underlying domains:

• Submission types and pathways: IND, NDA, BLA, ANDA, 510(k), PMA, De Novo
• CTD/eCTD structure: What goes in Modules 1–5 and why
• Regulatory frameworks: 21 CFR Parts 210/211 (manufacturing), 314 (NDAs), 601 (biologics)
• Labeling: Prescribing information structure, promotional review, labeling negotiations
• Regulatory strategy: Breakthrough Therapy, Fast Track, Accelerated Approval, REMS
• Post-market requirements: Adverse event reporting, post-marketing studies, label updates
• International: EMA CTD alignment, ICH guidelines, regional Module 1 differences

How Interviewers Actually Test You

Scenario questions (most common)

These test whether you can apply knowledge, not just recall it:

• "You're preparing an NDA for a small molecule. The FDA issues a Refuse to File letter citing deficiencies in Module 3. Walk me through how you'd handle it."
• "A post-approval safety signal triggers an FDA request for a labeling update. What process do you follow and who are your internal stakeholders?"
• "Your company wants Breakthrough Therapy Designation for a CNS asset. What criteria does it need to meet, and what does the designation actually get you?"

Technical deep-dives

• CTD/eCTD: "Walk me through the five modules of the CTD. What's the difference between Module 2 and Module 5?" (Module 2 = summaries/overviews written by the sponsor; Module 5 = actual clinical study reports)
• IND vs NDA: "What triggers a Type A meeting vs a Type B meeting with FDA?" (Type A = dispute resolution, clinical hold; Type B = pre-IND, pre-NDA/BLA, end of Phase 2)
• Device: "When does a 510(k) become insufficient and a company needs to file a PMA?" (When predicate doesn't exist or device raises new safety questions — Class III devices or novel Class II without predicate)
• Combination products: "Your drug-device combination product — who leads the regulatory submission, FDA CDER or CDRH?" (Primary mode of action determines lead center — if drug effect is primary, CDER leads)

Labeling questions (Pfizer, AstraZeneca, J&J ask these heavily)

• What's the difference between the Highlights section and the full PI?
• When does FDA require a REMS with Elements to Assure Safe Use (ETASU) vs a Medication Guide only?
• Walk me through a label negotiation process. What's your leverage as a sponsor?

Regulations You Must Know Cold

For pharma roles:

• 21 CFR Part 314 — NDA regulations (505(b)(1) vs 505(b)(2) vs 505(j) ANDA)
• 21 CFR Part 601 — Biologics/BLA
• 21 CFR Parts 210/211 — cGMP for finished pharmaceuticals
• ICH M4 — CTD structure
• ICH E3 — Clinical study report format
• ICH Q8/Q9/Q10 — Pharmaceutical development, risk management, quality systems

For medical device roles:

• 21 CFR Part 807 — 510(k) premarket notification
• 21 CFR Part 814 — PMA
• 21 CFR Part 820 — Quality System Regulation (QSR / cGMP for devices)
• ISO 14971 — Medical device risk management

For biotech/biologics roles:

• 21 CFR Part 600–610 — Biologics standards
• 351(a) vs 351(k) BLA pathway (reference product vs biosimilar)
• FDA guidance on biosimilarity and interchangeability

Real Interview Questions by Company Type

Large pharma (Pfizer, J&J, AbbVie):

• "Describe a time you managed a regulatory submission under a tight deadline. What did you prioritize and what did you deprioritize?"
• "What's the difference between a Complete Response Letter and a Refuse to File letter? Have you handled either?"
• "How do you approach a labeling negotiation where FDA and medical/commercial are misaligned internally?"

Mid-size biotech:

• "We're a lean team. You'd own IND through NDA for our lead asset. What does your first 90 days look like?"
• "We've never been through an FDA inspection. What's your approach to preparing the organization?"
• "Our CMC team says a manufacturing change won't require a Prior Approval Supplement. Do you agree? How do you evaluate that?"

Medical device (Medtronic, Boston Scientific, Abbott):

• "What predicate strategy would you use for a Class II cardiovascular device?"
• "Walk me through the 510(k) substantial equivalence argument for a device with modified indications."
• "When do you involve a Notified Body vs going direct to FDA?"

Regulatory Strategy Questions (Senior Roles)

Senior RA candidates are expected to speak to strategy, not just process:

• Accelerated Approval: Requires surrogate endpoint reasonably likely to predict clinical benefit; sponsor commits to confirmatory trial. Know Subpart H (drugs) and Subpart E (accelerated access).
• Breakthrough Therapy Designation: Requires preliminary clinical evidence of substantial improvement over existing therapy on at least one clinically significant endpoint. Gets intensive FDA guidance and rolling review.
• Fast Track: Broader — treats serious condition, fills unmet need. More frequent communication, rolling review.
• REMS: Know the difference between REMS with just a Medication Guide, REMS with communication plan, and REMS with ETASU. Be able to name therapeutic examples (isotretinoin — iPLEDGE; clozapine — CLOZAPIN REMS).

Know when to recommend each designation and when not to — interviewers flag candidates who default to "we should apply for Breakthrough" without understanding the burden.

Post-Market Questions

• "What are the timelines for IND safety reporting? An unexpected serious adverse event in a Phase 2 trial?"
  (7-day report for unexpected fatal/life-threatening SAEs; 15-day for other unexpected serious)
• "What triggers a Field Safety Corrective Action for a device vs a Drug Safety Communication for a drug?"
• "Your marketed product is mentioned in a case report suggesting a serious unlabeled adverse event. What's your process?"

Behavioral Questions (Don't Overlook These)

RA interviews weight behavioral questions heavily because the role requires cross-functional influence:

• "Tell me about a time you pushed back on a regulatory strategy proposed by the clinical or commercial team."
• "Describe a situation where you had conflicting input from FDA and EMA on the same submission. How did you resolve it?"
• "Give me an example of a mistake you made on a submission. What happened and what did you change?"

Use the STAR method, but make sure the "Result" includes a regulatory outcome — submission accepted, label approved, inspection passed — not a soft metric.

How to Structure Your Preparation

Two weeks out:

• Review all submission types relevant to the role (check the JD — is this drug, device, or combination?)
• Pull FDA guidance documents for the indication area the company works in — read them, don't just list them
• Know the company's pipeline: where are their assets in development? What submissions are coming up?

One week out:

• Practice 3–5 scenario questions out loud — record yourself
• Prepare two to three examples from your own experience for each core domain (submissions, labeling, strategy, post-market)
• Know the company's recent regulatory history: any Complete Response Letters? Any PDUFA dates coming up?

Day before:

• Review current FDA/EMA news — any new guidance documents, approval decisions, or regulatory actions in this therapeutic area?
• Prepare questions for the interviewer that show strategic thinking: "What's the biggest regulatory challenge in your pipeline right now?"

Common Mistakes

• Confusing regulatory strategy with regulatory operations — know which role you're interviewing for
• Over-citing regulations without connecting to application
• Not knowing the company's specific therapeutic area or product type
• Forgetting that RA is a cross-functional role — not showing you can influence without authority
• For device candidates: not knowing whether the company is domestic or internationally focused (EU MDR vs FDA pathway questions will differ)

Regulatory affairs rewards depth. The candidates who get offers can speak fluently about a submission they owned, the obstacles they hit, and the decisions they made — not just recite the CFR.

Practice your answers with AI-powered mock interviews that simulate the actual question format at CareerLift.ai.